ALK and non-small cell lung carcinoma: In the context of NSCLC, to be performant, an assay must be able to assess point mutations (EGFR-, BRAF V600E, ERBB2, and KRAS G12C mutations), exon skipping mutations (MET exon 14), and fusions or fusion transcripts (ALK-, ROS1-, RET-, NTRK-, and NRG1-rearrangements).